No Data
No Data
shenyang xingqi pharmaceutical (300573.SZ) plans to distribute a dividend of 5 yuan per 10 shares, with ex-rights and ex-dividend on October 16.
Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the company's interim equity distribution plan for the first half of 2024: to distribute 1...
Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Stock Retreats 32% But Earnings Haven't Escaped The Attention Of Investors
Tsubota Lab has signed an exclusive implementation license agreement with shenyang xingqi pharmaceutical.
On the 5th, Tobita Lab <4890> announced that they have signed a patent license agreement with China's ophthalmology drug manufacturer Shenyang Xingqi Pharmaceutical (hereinafter referred to as Xingqi) to grant exclusive rights to certain patents in specific regions.
A Look At The Fair Value Of Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573)
Shenyang Xingqi Pharmaceutical (300573.SZ): The first subject of the phase I clinical trial of SQ-22031 eye drops has been enrolled.
Gelonghui September 4th | Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the company's research and development of SQ-22031 eye drops recently completed the first subject enrolled in the "evaluation of the safety, tolerability and pharmacokinetics of SQ-22031 eye drops in healthy subjects for single/multiple doses in a Phase I clinical trial with a single center, randomized, double-blind, placebo-controlled design", officially entering the clinical trial. The Phase I study of SQ-22031 eye drops is a randomized, double-blind, placebo-controlled single/multiple dose trial to evaluate the safety of SQ-22031 eye drops in healthy subjects and analyze the evaluation.
Sinqi Pharmaceutical: Semi-Annual Report 2024
No Data
No Data